Germany Establishing a genuine European investment promotion platform is crucial Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment Promotion Agencies, discusses Germany’s evolving investment priorities, spanning healthcare, energy, digital technologies and mobility. He highlights the country’s strengths in…
Taiwan Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At the foundation of that achievement sits a network of domestic generic and OTC manufacturers, several of them family-owned businesses now…
Europe Europe is rewriting the rules governing medicines, innovation, and industrial competitiveness, with consequences that reach far beyond regulation alone. Pricing pressure from the United States, slower market access, rising administrative complexity, and the global race for biotech leadership are forcing policymakers to decide whether the region will remain a premier…
Brazil Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in January 2025, she has focused on navigating the rapidly transforming skincare landscape, balancing traditional physician relationships with emerging digital channels,…
France ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a resolutely medical positioning, early international expansion and a strategy built on proximity to clinicians and local partners. As the organisation…
Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…
Pharma Legal Handbook 1.Please make a general introduction to the public health sector in your country and its organization Saudi Arabia provides universal health coverage primarily funded by the government through a tax-based model. The healthcare system is organized in a tiered structure led by the Ministry of Health (MOH), which operates: •…
Pharma Legal Handbook Which are the administrations, bodies and institutions in charge of public health in your country and what are their respective responsibilities? The Ministry of Health (MOH) is the primary body responsible for public health in Saudi Arabia. It sets national health policies, issues licenses to healthcare providers (public and private),…
Pharma Legal Handbook What are the pricing models, processes and principles for originator drugs? Originator drugs (innovator medicines) are priced by the Saudi Food and Drug Authority (SFDA) following the principles outlined in its 2023 Drug Pricing Guidelines. The pricing process includes: External Reference Pricing (ERP): SFDA compares prices with a reference basket…
Pharma Legal Handbook What are the pricing models, processes and principles for originator drugs? Drugs are provided by a medical institution or pharmacy to a patient based on the NHI Drug Price (a patient pays 10%, 20% or 30% (depending on age and other conditions) of the NHI Drug Price). As detailed in…
Pharma Legal Handbook Have local authorities published recommendations surrounding value assessment dossiers? (If yes please add link) Yes. The SFDA published the Economic Evaluation Studies Guideline (PDF, July 10, 2024), which outlines comprehensive methods and includes a checklist. Followed by the Pharmacoeconomic Submission Portal Manual (January 2025), detailing dossier preparation and submission protocols.…
Pharma Legal Handbook In addition to the clinical data obtained through clinical studies please list the data required for a. Market approval In addition to clinical trial data, the following documents are required for market authorization in Saudi Arabia: Quality/CMC Module: Includes full GMP certificates (PIC/S or WHO type) and a local…
See our Cookie Privacy Policy Here